M
Melvyn Lynn
Researcher at Eisai
Publications - 32
Citations - 2241
Melvyn Lynn is an academic researcher from Eisai. The author has contributed to research in topics: Eritoran & Lipid A. The author has an hindex of 17, co-authored 32 publications receiving 2138 citations.
Papers
More filters
Journal ArticleDOI
Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial.
Steven M. Opal,Pierre-François Laterre,Bruno François,Steven P. LaRosa,Derek C. Angus,Jean-Paul Mira,Xavier Wittebole,Thierry Dugernier,Dominique Perrotin,Mark Tidswell,Luis Jauregui,Kenneth Krell,Jan Pachl,Takahashi Takeshi,Claus Peckelsen,Edward Cordasco,Chia-Sheng Chang,Sandra Oeyen,Naoki Aikawa,Tatsuya Maruyama,Roland M. H. Schein,Andre C. Kalil,Marc Van Nuffelen,Melvyn Lynn,Daniel P. Rossignol,Jagadish Gogate,Mary B. Roberts,Mary B. Roberts,Janice L. Wheeler,Jean Louis Vincent +29 more
TL;DR: Among patients with severe sepsis, the use of eritoran, compared with placebo, did not result in reduced 28-day mortality, and no significant differences were observed in any of the prespecified subgroups.
Effect of Eritoran, an Antagonist of MD2-TLR4, on Mortality in Patients With Severe Sepsis
Steven M. Opal,Pierre-François Laterre,Bruno François,Steven P. LaRosa,Derek C. Angus,Jean-Paul Mira,Xavier Wittebole,Thierry Dugernier,Dominique Perrotin,Mark Tidswell,Luis Jauregui,Kenneth Krell,Jan Pachl,Takahashi Takeshi,Claus Peckelsen,Edward Cordasco,Chia-Sheng Chang,Sandra Oeyen,Naoki Aikawa,Tatsuya Maruyama,Roland M. H. Schein,Andre C. Kalil,Marc Van Nuffelen,Melvyn Lynn,Daniel P. Rossignol +24 more
TL;DR: Steven M. Opal, MDPierre-Francois Laterre, MDBruno Francois, MDSteven P. LaRosa, MDDerek C. Kalil, MD, MPHMarc Van Nuffelen, MDMelvyn Lynn, PhDDaniel P. Rossignol, PhDJogadish Gogate, PhDMary B. Roberts, MSJanice L. Wheeler, BS, RNJean-Louis Vincent, MD as discussed by the authors
Journal ArticleDOI
Phase 2 trial of eritoran tetrasodium (E5564), a toll-like receptor 4 antagonist, in patients with severe sepsis.
Mark Tidswell,William Tillis,Steven P. LaRosa,Melvyn Lynn,AE Wittek,Richard Kao,Janice L. Wheeler,Jagadish Gogate,Steven M. Opal +8 more
TL;DR: The observed trend toward a lower mortality rate at the 105-mg dose, in subjects with severe sepsis and high predicted risk of mortality, should be further investigated.
Journal ArticleDOI
Blocking of responses to endotoxin by E5564 in healthy volunteers with experimental endotoxemia
Melvyn Lynn,Daniel P. Rossignol,Janice L. Wheeler,Richard Kao,Carlos Perdomo,Robert J. Noveck,Ramon Vargas,Tony D’Angelo,Sandra Gotzkowsky,F. Gilbert McMahon +9 more
TL;DR: It is demonstrated that E5564 blocks the effects of LPS in a human model of clinical sepsis and indicate its potential in the treatment and/or prevention of clinicalSepsis.
Journal ArticleDOI
Antagonism of in vivo and ex vivo response to endotoxin by E5564, a synthetic lipid A analogue.
Daniel P. Rossignol,Melvyn Lynn +1 more
TL;DR: Results from these multiple-dose studies indicate that under these conditions of administration, plasma levels of E5564 can be predictive of long-term pharmacodynamic activity.